Last reviewed · How we verify
NCT03667300: DA1229
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency
Phase 2 trial testing Evogliptin in Type2 Diabetes Mellitus in 209 participants. Completed in 14 May 2019.
14 May 2019
Quick facts
| Lead sponsor | Samsung Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 209 |
| Start date | 16 March 2017 |
| Primary completion | 14 May 2019 |
| Estimated completion | 14 May 2019 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Evogliptin (EVOGLIPTIN) — full drug profile →
- Linagliptin (LINAGLIPTIN) — full drug profile →
Conditions studied
- Type2 Diabetes Mellitus — all drugs for Type2 Diabetes Mellitus →
- Albuminuria — all drugs for Albuminuria →
- Renal Insufficiency — all drugs for Renal Insufficiency →
Sponsor
Samsung Medical Center
Who can join
20 and older, any sex, with Type2 Diabetes Mellitus or Albuminuria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this multi-center, randomized, double-blind, active-controlled, phase II non-inferiority study, we aimed to test the non-inferiority of evogliptin vs linagliptin in terms of reduction of albuminuria at week 24 from baseline in patients with type 2 diabetes having renal insufficiency.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03667300
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Evogliptin
Trials testing the same drug.
- NCT05143177 — A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild · Phase 2, PHASE3 · suspended
- NCT04706637 — A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin · Phase 4 · unknown
- NCT04326166 — Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab. · unknown
- NCT03910361 — Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases · Phase 4 · completed
- NCT02689362 — Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) · Phase 2 · completed
Other recruiting trials for Type2 Diabetes Mellitus
Currently open trials in the same condition.
- NCT07533604 — SnapDandCGMinType2Diabetes · NA · recruiting
- NCT06961019 — Clinical Study to Assess the Safety, Efficacy and In-Use Tolerability of Herbal-Based Sugar Support Effervescent Tablets · NA · recruiting
- NCT06497842 — Effort During Resistance Training in Type 2 Diabetes · NA · active not recruiting
- NCT06257966 — A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type · Phase 3 · active not recruiting
- NCT03647306 — Behavioral Chronotype: Impact on Sleep and Metabolism · NA · active not recruiting
Other Samsung Medical Center trials
Trials by the same sponsor.
- NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
- NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
- NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
- NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
- NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03667300 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
- Last refreshed: 23 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03667300.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing